No association between migraine and breast cancer risk
the ONA take:
According to a new study published in the Journal of the National Cancer Institute, researchers at Harvard University Medical School in Boston, Massachusetts, have found that there is no associated between migraines and risk of breast cancer.
For the studies, researchers analyzed four other studies that included over 100,000 women actually found that migraines may decrease the risk of breast cancer, but researchers note that this finding may be due to study design rather than a real association.
The theory that there was a link between migraines and risk of breast cancer comes up from the notion that both arise from increased sex hormone levels. When the research team analyzed the levels of sex hormones in about 2,000 premenopausal women who experience migraines, the researchers found no link between the two.
According to the Migraine Research Foundation, approximately 18% of American women and 6% of American men experience migraines. A migraine is a severe headache that is often accompanied by sensitivity to light and sound, nausea, visual disturbances, and vomiting. A migraine can last anywhere between 4 hour and 3 days.
There is no associated between migraines and risk of breast cancer.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Caregiver Mastery Linked to Patient Survival in Glioblastoma
- Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma
- Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|